19 May 2013
Keywords: b-ms, licenses, novartis, hiv, protease, inhibitors, bristol-myers
Article | 09 June 1997
Bristol-Myers Squibb has licensed two HIV protease inhibitors fromNovartis, in a bid to flesh out its portfolio of antiretrovirals. The
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
9 June 1997
17 May 2013
© 2013 thepharmaletter.com